Amgen stock
AMGNNASDAQAmgen Inc., HealthcareISIN US0311621009
76Score 76 out of 100, Strong
Price and trend
80 / 100
Price history
+39% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 68).
The price is 2.4% below its 52-week high. Largest decline in 20 years: 47% (January 2007 to March 2008).
Chart figures for advanced users
- SMA 50$424.87
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$380.39
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)68
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$313.85
- The lowest closing price of the last twelve months.
- Resistance$478.48
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Amgen Inc. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $252.64B, is number 8 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $36.74B (up 9.9% year on year) and earnings of $7.71B (up 88.5%).
- For fiscal 2026, analysts expect on average revenue of $39.43B (up 7.3%) and adjusted earnings per share of $23.50 (up 7.5%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 48 of 702 in Healthcare, median 53.
- The P/E is 27.2 (Drug Manufacturers (General) median 25.7, own median of recent years 21.7).
- Our model puts fair value at $446.76, with the price 5% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 15 years.Capital allocation 91
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 94
- Share buybacksShare count down 8% since 2020.Capital allocation 91
Weaknesses
- High debtDebt 3.76 times equity (latest quarter), Drug Manufacturers (General) median 1.2.Stability 47
Its standout strengths are fundamentals and profitability, while stability and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 77 to 76.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- very large company
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $343.66 and expensive above $638.23 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $451.14 (cash-flow model) and $442.37 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $408.14, at 7.8% it would be $504.77.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.3% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 71%, operating 29%, net 21%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Feb 2027in 81 days
- Last reported
- 3 Nov 2026EPS reported $6.45 (expected $5.79)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $23.15+0.5%
- Revenue
- $39.09B+0.2%
- Earnings per share
- $24.62+0.4%
- Revenue
- $40.68B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +7.6%2026 guidance raised: revenue $38.2 billion to $39.4 billion, non-GAAP EPS $22.30 to $23.50.
The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $2.48M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Khosla RachnaSale
13 Aug 2026, SVP, Business Development
- Shares
- 1,252
- Price
- $416.43
- Value
- $521,365
- Khosla RachnaSale
11 Aug 2026, SVP, Business Development
- Shares
- 2,000
- Price
- $412.57
- Value
- $825,134
- Miller DerekSale
6 Aug 2026, SVP, Human Resources
- Shares
- 1,821
- Price
- $402.54
- Value
- $733,033
Show 1 more
- Grygiel Nancy A.Sale
6 Aug 2026, SVP & CCO
- Shares
- 1,000
- Price
- $402.16
- Value
- $402,160
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Amgen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Roche HoldingROP.SW $394.85B77
- MerckMRK $362.27B68
- NovartisNOVN.SW $304.26B75
- AstraZenecaAZN $285.95B73
- Gilead SciencesGILD $208.31B57
- Novo NordiskNOVO-B.CO $180.19B79
- PfizerPFE $164.33B60
- Bristol-Myers SquibbBMY $127.39B70
ETFs that hold Amgen
Held by 151 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 8.57% | 0.35% | €1.21B |
| iShares Dow Jones Industrial Average UCITS ETF (DE)EXI3 | 5.29% | 0.51% | €322.26M |
| Global X S&P 500 Covered Call UCITS ETF IncXY7D | 4.67% | 0.45% | €203.27M |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 3.74% | 0.12% | €1.34B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 3.71% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 3.70% | 0.15% | €3.29B |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 2.70% | 0.25% | €4.12B |
| L&G Pharma Breakthrough UCITS ETFETLI | 2.69% | 0.49% | €26.29M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.